Search
for
Sort by
Research 271–300 of 1000+
- Abstract 1835: Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3 (WHSC1L1)
- Medical management of benign prostatic hyperplasia
- Medico-Surgical Therapeutic Management of Benign Prostatic Hyperplasia
- Update on medical management of benign prostatic hyperplasia
- A case of finasteride-induced hyperplasia of mammary glands
- Novel <i>ABCD1</i> Gene Mutation in Adrenomyeloneuropathy with Hypoplasia and Agenesis of the Corpus Callosum
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia
- The Effect of Finasteride in Men with Benign Prostatic Hyperplasia
- Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFα expression in transgenic mice
- Epidemiology and treatment modalities for the management of benign prostatic hyperplasia
- Finasteride in the treatment of patients with benign prostatic hyperplasia: a review
- Medical Treatment of Recurrent Intussusception Associated With Intestinal Lymphoid Hyperplasia
- A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia
- Medical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
- Evaluation of Sex Hormone Levels in Benign Prostatic Hyperplasia Patients Treated with 5 Alpha-Reductase Inhibitor (Finasteride) in Amara city/Iraq
- Finasteride: Middle-Age Cure-All for Alopecia and Benign Prostatic Hyperplasia?–Reply–I
- The relevance of using 5α-reductase inhibitors in the conservative management of benign prostatic hyperplasia: A review
- Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia
- Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
- A Review on Steroidal 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia
- Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
- Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia
- Pathogenetic justification of the use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
- Hemorrhagic Cystitis in Allogeneic Stem Cell Transplantation: A Role for Age and Prostatic Hyperplasia
- Management of Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia During and After COVID-19
- Effect of metabolic syndrome on treatment outcome of lower urinary tract symptoms in males due to benign prostatic hyperplasia
- 5-alpha reductase inhibitors: New evidences on benefits and harms beyond benign prostatic hyperplasia
- Effects of androgen overproduction on skin target organs in children with congenital adrenal hyperplasia
- Risk of New-Onset Postoperative Depression After Holmium Laser Enucleation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Nationwide Retrospective Cohort Study
- Therapeutic Effect of Brain Awakening and Mind Opening Acupuncture Combined with Simiao Pill on Mice with Benign Prostatic Hyperplasia